 THE WOODLANDS, Texas, Dec. 31, 2020 GLOBE NEWSWIRE -- Lexicon Pharmaceuticals, Inc. Nasdaq: LXRX, announced today the commencement of patient dosing in RELIEF-PHN 1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of LX9211 for the treatment of post-herpetic neuralgia. LX9211 is a potent oral small molecule inhibitor of adaptor associated kinase 1 AAK1. 